Vismodegib

Drug Overview

Vismodegib (brand name Erivedge) is a first-in-class, orally bioavailable small molecule that functions as a selective Hedgehog pathway inhibitor. Developed by Genentech, it represents a landmark achievement in targeted therapy, specifically designed to combat the underlying genetic drivers of Basal Cell Carcinoma (BCC). It was the first medicine ever approved by the FDA to treat advanced forms of the most common cancer in the world.

In the clinical landscape of March 2026, vismodegib is recognized as the gold standard for patients with BCC that is either metastatic or locally advanced to a degree where surgery or radiation is no longer a viable option. By targeting a specific protein called SMO (Smoothened), vismodegib “turns off” the signals that tell cancer cells to multiply, providing a vital lifeline for patients with extensive skin involvement or the rare genetic condition known as Gorlin Syndrome.

• Generic Name: Vismodegib.
• Brand Name: Erivedge.
• Drug Class: Hedgehog Pathway Inhibitor; Antineoplastic Agent.
• Target: Smoothened (SMO) protein.
• Route of Administration: Oral (Capsule).
• FDA Approval Status: FDA-approved (Initial approval: January 2012).

What Is It and How Does It Work? (Mechanism of Action)

Vismodegib is a “molecular switch” that targets the Hedgehog signaling pathway, a biological system that is essential during human embryonic development but is usually “silenced” in healthy adult tissues.

1. The Hedgehog Pathway Hijack

In over 90% of Basal Cell Carcinomas, this pathway is inappropriately reactivated due to genetic mutations. These mutations (typically in the PTCH1 or SMO genes) act like a broken gas pedal, sending constant “grow” signals to the skin cells.

2. Molecular Level Mechanisms

1. SMO Binding: Vismodegib enters the cell and binds specifically to the Smoothened (SMO) transmembrane protein.
2. Signal Blockade: By binding to SMO, the drug prevents the protein from activating downstream transcription factors called GLI proteins.
3. Transcriptional Silencing: Without GLI activation, the cell can no longer turn on the genes required for proliferation and survival.
4. Tumor Regression: The lack of these signals leads to a dramatic halt in tumor growth and, in many cases, significant shrinkage of even the most extensive skin lesions.

FDA Approved Clinical Indications

Vismodegib is indicated for adults with specific, high-risk presentations of Basal Cell Carcinoma where local treatments (like Mohs surgery) have reached their limit.

• Metastatic Basal Cell Carcinoma: For cancer that has spread to distant organs or lymph nodes.
• Locally Advanced Basal Cell Carcinoma (laBCC): For tumors that have recurred following surgery or those that are so large/deep that surgery or radiation would result in severe disfigurement or loss of function.
• Gorlin Syndrome (Basal Cell Nevus Syndrome): While used off-label or in specialized protocols, it is a critical therapy for these patients who can develop hundreds of BCCs over their lifetime.

Dosage and Administration Protocols

Vismodegib is designed for convenient, once-daily oral administration, though it requires strict adherence to safety protocols.

Clinical Efficacy and Research Results

Clinical findings spanning over a decade, updated through 2025–2026, demonstrate the profound impact of vismodegib on advanced skin cancer.

• Response Rates: In the pivotal ERIVANCE trial, the objective response rate was approximately 43% for metastatic disease and 60% for locally advanced disease. Some patients experience complete clinical clearance of visible tumors.
• Disease Control: The median duration of response is often over 20 months, providing long-term stabilization for a condition that was previously difficult to manage.
• Resistance Research: In 2026, research is heavily focused on “acquired resistance.” Some tumors develop new mutations in the SMO protein that “kick” the vismodegib out. This has led to the development of second-generation Hedgehog inhibitors.

Safety Profile and Side Effects

Because the Hedgehog pathway is involved in maintaining certain healthy tissues (like taste buds and hair follicles), vismodegib has a unique and frequent side effect profile.

Common Side Effects (>30%):

• Dysgeusia (Taste Disturbance): Loss of taste or a constant metallic taste; this is often the most frustrating side effect for patients.
• Muscle Spasms: Frequent, sometimes painful cramps, particularly in the legs.
• Alopecia (Hair Loss): Thinning or complete loss of body and scalp hair.
• Weight Loss and Fatigue: General systemic impact on appetite and energy levels.

Serious Risks & Boxed Warning:

• Embryo-Fetal Toxicity (Boxed Warning): Vismodegib can cause severe birth defects or fetal death. It is strictly contraindicated in pregnancy.
• Blood Donation Prophylaxis: Patients must not donate blood while on the drug and for 24 months after the final dose to ensure it is never inadvertently given to a pregnant woman.
• Amenorrhea: In women of childbearing potential, vismodegib can cause the cessation of menstrual cycles, which may not be reversible.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, vismodegib is a vital tool for studying “Cancer Stem Cell Niche Signaling.” Basal Cell Carcinoma is thought to arise from hair follicle stem cells. Researchers are using vismodegib to understand how inhibiting Hedgehog signals forces these malignant stem cells into “senescence” (permanent sleep). Furthermore, 2026 research is exploring vismodegib as a neoadjuvant (pre-surgery) therapy. By shrinking a massive tumor with the drug first, surgeons may be able to perform much smaller, less disfiguring operations.

Patient Management and Practical Recommendations

Pre-treatment Tests:

• Pregnancy Test: Mandatory for females of reproductive potential within 7 days of starting treatment.
• Renal/Hepatic Panel: To establish baseline organ function, although vismodegib is generally well-tolerated by these systems.

“Do’s and Don’ts” List:

• DO use highly effective contraception. Females should use it during treatment and for 7 months after the last dose; males should use condoms with pregnant or potentially pregnant partners for 3 months post-treatment.
• DO stay hydrated and consider magnesium supplements (as directed by a doctor) to help manage muscle spasms.
• DON’T open the capsules; the medication is hazardous and can be absorbed through the skin.
• DON’T donate blood, even years after stopping treatment, until you have cleared the mandatory 24-month waiting period.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Vismodegib is a potent targeted therapy with significant risks, particularly regarding fetal safety. Always consult with a qualified dermatologist or oncologist regarding your specific diagnosis and treatment plan.